Wellness products company Nature’s Sunshine (NASDAQ: NATR) will be reporting earnings this Thursday afternoon. Here’s what you need to know.
Nature's Sunshine beat analysts’ revenue expectations by 2.2% last quarter, reporting revenues of $114.8 million, up 3.8% year on year. It was a very strong quarter for the company, with a beat of analysts’ EPS estimates and an impressive beat of analysts’ EBITDA estimates.
Is Nature's Sunshine a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Nature's Sunshine’s revenue to grow 5% year on year to $120.3 million, improving from the 3.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.16 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Nature's Sunshine has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time since going public by 2.9% on average.
Looking at Nature's Sunshine’s peers in the personal care segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Estée Lauder delivered year-on-year revenue growth of 3.5%, beating analysts’ expectations by 2.9%, and Medifast reported a revenue decline of 36.2%, in line with consensus estimates. Estée Lauder’s stock price was unchanged after the resultsand Medifast’s price followed a similar reaction.
Read our full analysis of Estée Lauder’s results here and Medifast’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the personal care stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 6.3% on average over the last month. Nature's Sunshine is down 9.5% during the same time and is heading into earnings with an average analyst price target of $21.50 (compared to the current share price of $13.75).
P.S. STOP buying the AI stocks everyone’s talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
